Studies of elderly subjects using biomarkers that are proxies for Alzheimer’s disease (AD) pathology have the potential to document meaningful relationships between cognitive performance and biomarker changes along the AD continuum.
Objective:
To document cognitive performance differences across distinct AD stages using a categorization based on the presence of PET-assessed amyloid-β (Aβ) burden and neurodegeneration.
Methods:
Patients with mild dementia compatible with AD (n = 38) or amnestic mild cognitive impairment (aMCI; n = 43) and a cognitively unimpaired group (n = 27) underwent PET with Pittsburgh compound-B (PiB) assessing Aβ aggregation (A+) and [18F]FDG-PET assessing neurodegeneration ((N)+). Cognitive performance was assessed with verbal and visual episodic memory tests and the Mini-Mental State Examination.
Results:
The A+(N)+ subgroup (n = 32) showed decreased (p < 0.001) cognitive test scores compared to both A+(N)–(n = 18) and A–(N)–(n = 49) subjects, who presented highly similar mean cognitive scores. Despite its modest size (n = 9), the A–(N)+ subgroup showed lower (p < 0.043) verbal memory scores relative to A–(N)–subjects, and trend lower (p = 0.096) scores relative to A+(N)–subjects. Continuous Aβ measures (standard uptake value ratios of PiB uptake) were correlated most significantly with visual memory scores both in the overall sample and when analyses were restricted to dementia or (N)+ subjects, but not in non-dementia or (N)–groups.
Conclusion:
These results demonstrate that significant Aβ-cognition relationships are highly salient at disease stages involving neurodegeneration. The fact that findings relating Aβ burden to memory performance were detected only at (N)+ stages, together with the similarity of test scores between A+(N)–and A–(N)–subjects, reinforce the view that Aβ-cognition relationships during early AD stages may remain undetectable unless substantially large samples are evaluated.
HymanBT, PhelpsCH, BeachTG, BigioEH, CairnsNJ, CarrilloMC, DicksonDW, DuyckaertsC, FroschMP, MasliahE, MirraSS, NelsonPT, SchneiderJA, ThalDR, ThiesB, TrojanowskiJQ, VintersH V, MontineTJ (2012) National Institute on Aging-Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease. Alzheimers Dement8, 1–13.
2.
SperlingRA, AisenPS, BeckettLA, BennettDA, CraftS, FaganAM, IwatsuboT, JackCR, KayeJ, MontineTJ, ParkDC, ReimanEM, RoweCC, SiemersE, SternY, YaffeK, CarrilloMC, ThiesB, Morrison-BogoradM, WagsterMV, PhelpsCH (2011) Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement7, 280–292.
3.
JansenWJ, OssenkoppeleR, KnolDL, TijmsBM, ScheltensP, VerheyFR, VisserPJ; Amyloid Biomarker Study Group, AaltenP, AarslandD, AlcoleaD, AlexanderM, AlmdahlIS, ArnoldSE, BaldeirasI, BarthelH, van BerckelBN, BibeauK, BlennowK, BrooksDJ, van BuchemMA, CamusV, CavedoE, ChenK, ChetelatG, CohenAD, DrzezgaA, EngelborghsS, FaganAM, FladbyT, FleisherAS, van der FlierWM, FordL, FörsterS, ForteaJ, FoskettN, FrederiksenKS, Freund-LeviY, FrisoniGB, FroelichL, GabryelewiczT, GillKD, GkatzimaO, Gómez-TortosaE, GordonMF, GrimmerT, HampelH, HausnerL, HellwigS, HerukkaSK, HildebrandtH, IshiharaL, IvanoiuA, JagustWJ, JohannsenP, KandimallaR, KapakiE, Klimkowicz-MrowiecA, KlunkWE, KöhlerS, KoglinN, KornhuberJ, KrambergerMG, Van LaereK, LandauSM, LeeDY, de LeonM, LisettiV, LleóA, MadsenK, MaierW, MarcussonJ, MattssonN, de MendonçaA, MeulenbroekO, MeyerPT, MintunMA, MokV, MolinuevoJL, MøllergårdHM, MorrisJC, MroczkoB, Van der MusseleS, NaDL, NewbergA, NordbergA, NordlundA, NovakGP, ParaskevasGP, ParnettiL, PereraG, PetersO, PoppJ, PrabhakarS, RabinoviciGD, RamakersIH, RamiL, Resende de OliveiraC, RinneJO, RodrigueKM, Rodríguez-RodríguezE, RoeCM, RotU, RoweCC, RütherE, SabriO, Sanchez-JuanP, SantanaI, SarazinM, SchröderJ, SchütteC, SeoSW, SoeteweyF, SoininenH, SpiruL, StruyfsH, TeunissenCE, TsolakiM, VandenbergheR, VerbeekMM, VillemagneVL, VosSJ, van Waalwijk van DoornLJ, WaldemarG, WallinA, WallinÅK, WiltfangJ, WolkDA, ZbochM, ZetterbergH (2015) Prevalence of cerebral amyloid pathology in persons without dementia: A meta-analysis. JAMA313, 1924–1938.
4.
JackCR, WisteHJ, WeigandSD, RoccaWA, KnopmanDS, MielkeMM, LoweVJ, SenjemML, GunterJL, PreboskeGM, PankratzVS, VemuriP, PetersenRC (2014) Age-specific population frequencies of cerebral β-amyloidosis and neurodegeneration among people with normal cognitive function aged 50–89 years: A cross-sectional study. Lancet Neurol13, 997–1005.
WeigandAJ, ThomasKR, BangenKJ, EglitGML, Delano-WoodL, GilbertPE, BrickmanAM, BondiMW (2019) APOE interacts with tau PET to influence memory independently of amyloid PET. medRxiv 19008318; doi: https://doi.org/10.1101/19008318
8.
NelsonPT, AlafuzoffI, BigioEH, BourasC, BraakH, CairnsNJ, CastellaniRJ, CrainBJ, DaviesP, Del TrediciK, DuyckaertsC, FroschMP, HaroutunianV, HofPR, HuletteCM, HymanBT, IwatsuboT, JellingerKA, JichaGA, KövariE, KukullWA, LeverenzJB, LoveS, MackenzieIR, MannDM, MasliahE, McKeeAC, MontineTJ, MorrisJC, SchneiderJA, SonnenJA, ThalDR, TrojanowskiJQ, TroncosoJC, WisniewskiT, WoltjerRL, BeachTG (2012) Correlation of Alzheimer disease neuropathologic changes with cognitive status: A review of the literature. J Neuropathol Exp Neurol71, 362–381.
9.
EnglerH, ForsbergA, AlmkvistO, BlomquistG, LarssonE, SavitchevaI, WallA, RingheimA, LångströmB, NordbergA (2006) Two-year follow-up of amyloid deposition in patients with Alzheimer’s disease. Brain129, 2856–2866.
10.
EdisonP, ArcherHA, HinzR, HammersA, PaveseN, TaiYF, HottonG, CutlerD, FoxN, KennedyA, RossorM, BrooksDJ (2007) Amyloid, hypometabolism, and cognition in Alzheimer disease: An [11C]PIB and [18F]FDG PET study. Neurology68, 501–508.
11.
ForsbergA, EnglerH, AlmkvistO, BlomquistG, HagmanG, WallA, RingheimA, LångströmB, NordbergA (2008) PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol Aging29, 1456–1465.
12.
RamiL, ForteaJ, BoschB, Solé-PadullésC, LladóA, IranzoA, Sánchez-ValleR, MolinuevoJL (2011) Cerebrospinal fluid biomarkers and memory present distinct associations along the continuum from healthy subjects to AD patients. J Alzheimers Dis23, 319–326.
13.
SperlingRA, JohnsonKA, DoraiswamyPM, ReimanEM, FleisherAS, SabbaghMN, SadowskyCH, CarpenterA, DavisMD, LuM, FlitterM, JoshiAD, ClarkCM, GrundmanM, MintunMA, SkovronskyDM, PontecorvoMJ, AV45-A05 Study Group (2013) Amyloid deposition detected with florbetapir F 18 ((18)F-AV-45) is related to lower episodic memory performance in clinically normal older individuals. Neurobiol Aging34, 822–831.
14.
HeddenT, OhH, YoungerAP, PatelTA (2013) Meta-analysis of amyloid-cognition relations in cognitively normal older adults. Neurology80, 1341–1348.
15.
PetersenRC, WisteHJ, WeigandSD, RoccaWA, RobertsRO, MielkeMM, LoweVJ, KnopmanDS, PankratzVS, MachuldaMM, GedaYE, JackCR (2016) Association of elevated amyloid levels with cognition and biomarkers in cognitively normal people from the community. JAMA Neurol73, 85–92.
16.
JansenWJ, OssenkoppeleR, TijmsBM, FaganAM, HanssonO, KlunkWE, van der FlierWM, VillemagneVL, FrisoniGB, FleisherAS, LleóA, MintunMA, WallinA, EngelborghsS, NaDL, ChételatG, MolinuevoJL, LandauSM, MattssonN, KornhuberJ, SabriO, RoweCC, ParnettiL, PoppJ, FladbyT, JagustWJ, AaltenP, LeeDY, VandenbergheR, Resende de OliveiraC, KapakiE, FroelichL, IvanoiuA, GabryelewiczT, VerbeekMM, Sanchez-JuanP, HildebrandtH, CamusV, ZbochM, BrooksDJ, DrzezgaA, RinneJO, NewbergA, de MendonçaA, SarazinM, RabinoviciGD, MadsenK, KrambergerMG, NordbergA, MokV, MroczkoB, WolkDA, MeyerPT, TsolakiM, ScheltensP, VerheyFRJ, VisserPJ; Amyloid Biomarker Study Group, AarslandD, AlcoleaD, AlexanderM, AlmdahlIS, ArnoldSE, BaldeirasI, BarthelH, van BerckelBNM, BlennowK, van BuchemMA, CavedoE, ChenK, ChipiE, CohenAD, FörsterS, ForteaJ, FrederiksenKS, Freund-LeviY, GkatzimaO, GordonMF, GrimmerT, HampelH, HausnerL, HellwigS, HerukkaSK, JohannsenP, Klimkowicz-MrowiecA, KöhlerS, KoglinN, van LaereK, de LeonM, LisettiV, MaierW, MarcussonJ, MeulenbroekO, MøllergårdHM, MorrisJC, NordlundA, NovakGP, ParaskevasGP, PereraG, PetersO, RamakersIHGB, RamiL, Rodríguez-RodríguezE, RoeCM, RotU, RütherE, SantanaI, SchröderJ, SeoSW, SoininenH, SpiruL, StomrudE, StruyfsH, TeunissenCE, VosSJB, van Waalwijk van DoornLJC, WaldemarG, WallinÅK, WiltfangJ, ZetterbergH (2018) Association of cerebral amyloid-β aggregation with cognitive functioning in persons without dementia. JAMA Psychiatry75, 84–95.
17.
CiarmielloA, TartaglioneA, GiovanniniE, RiondatoM, GiovacchiniG, FerrandoO, De BiasiM, PasseraC, CarabelliE, MannironiA, FoppianoF, AlfanoB, MansiL (2019) Amyloid burden identifies neuropsychological phenotypes at increased risk of progression to Alzheimer’s disease in mild cognitive impairment patients. Eur J Nucl Med Mol Imaging46, 288–296.
18.
SperlingRA, MorminoEC, SchultzAP, BetenskyRA, PappK V, AmariglioRE, HanseeuwBJ, BuckleyR, ChhatwalJ, HeddenT, MarshallGA, QuirozYT, DonovanNJ, JacksonJ, GatchelJR, RabinJS, JacobsH, YangHS, ProperziM, KirnDR, RentzDM, JohnsonKA (2019) The impact of amyloid-beta and tau on prospective cognitive decline in older individuals. Ann Neurol85, 181–193.
19.
AizensteinHJ, NebesRD, SaxtonJA, PriceJC, MathisCA, TsopelasND, ZiolkoSK, JamesJA, SnitzBE, HouckPR, BiW, CohenAD, LoprestiBJ, DeKoskyST, HalliganEM, KlunkWE (2008) Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch Neurol65, 1509–1517.
20.
JackCR, LoweVJ, SenjemML, WeigandSD, KempBJ, ShiungMM, KnopmanDS, BoeveBF, KlunkWE, MathisCA, PetersenRC (2008) 11C PiB and structural MRI provide complementary information in imaging of Alzheimer’s disease and amnestic mild cognitive impairment. Brain131, 665–680.
21.
StorandtM, MintunMA, HeadD, MorrisJC (2009) Cognitive decline and brain volume loss as signatures of cerebral amyloid-beta peptide deposition identified with Pittsburgh compound B: Cognitive decline associated with Abeta deposition. Arch Neurol66, 1476–1481.
22.
RoweCC, EllisKA, RimajovaM, BourgeatP, PikeKE, JonesG, FrippJ, Tochon-DanguyH, MorandeauL, O’KeefeG, PriceR, RanigaP, RobinsP, AcostaO, LenzoN, SzoekeC, SalvadoO, HeadR, MartinsR, MastersCL, AmesD, VillemagneVL (2010) Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol Aging31, 1275–1283.
23.
FariaDP, DuranFL, SquarzoniP, CoutinhoAM, GarcezAT, SantosPP, BruckiSM, de OliveiraMO, TrésES, ForlenzaO V, NitriniR, BuchpiguelCA, BusattoFilho G (2019) Topography of 11C-Pittsburgh compound B uptake in Alzheimer’s disease: A voxel-based investigation of cortical and white matter regions. Braz J Psychiatry41, 101–111.
MosconiL, TsuiWH, HerholzK, PupiA, DrzezgaA, LucignaniG, ReimanEM, HolthoffV, KalbeE, SorbiS, Diehl-SchmidJ, PerneczkyR, ClericiF, CaselliR, Beuthien-BaumannB, KurzA, MinoshimaS, de LeonMJ (2008) Multicenter standardized 18F-FDG PET diagnosis of mild cognitive impairment, Alzheimer’s disease, and other dementias. J Nucl Med49, 390–398.
26.
McKhannGM, KnopmanDS, ChertkowH, HymanBT, JackCR, KawasCH, KlunkWE, KoroshetzWJ, ManlyJJ, MayeuxR, MohsRC, MorrisJC, RossorMN, ScheltensP, CarrilloMC, ThiesB, WeintraubS, PhelpsCH (2011) The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement7, 263–269.
27.
GuzeS (2006) Diagnostic and Statistical Manual of Mental Disorders, 4th ed. (DSM-IV).
28.
FolsteinMF, FolsteinSE, McHughPR (1975) “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res12, 189–198.
29.
BlessedG, TomlinsonBE, RothM (1968) The association between quantitative measures of dementia and of senile change in the cerebral grey matter of elderly subjects. Br J Psychiatry114, 797–811.
30.
JormAF, JacombPA (1989) The Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE): Socio-demographic correlates, reliability, validity and some norms. Psychol Med19, 1015–1022.
31.
MoroneyJT, BagiellaE, DesmondDW, HachinskiVC, MölsäPK, GustafsonL, BrunA, FischerP, ErkinjunttiT, RosenW, PaikMC, TatemichiTK (1997) Meta-analysis of the Hachinski Ischemic Score in pathologically verified dementias. Neurology49, 1096–1105.
AlbertMS, DeKoskyST, DicksonD, DuboisB, FeldmanHH, FoxNC, GamstA, HoltzmanDM, JagustWJ, PetersenRC, SnyderPJ, CarrilloMC, ThiesB, PhelpsCH (2011) The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement7, 270–279.
34.
Del-BenCM, VilelaJAA, CrippaJA de S, HallakJEC, LabateCM, ZuardiAW (2001) Reliability of the structured clinical interview for DSM-IV - Clinical version translated into Portuguese. Braz J Psychiatry23, 156–159.
35.
CoutinhoAM, BusattoGF, de Gobbi PortoFH, de Paula FariaD, OnoCR, GarcezAT, SquarzoniP, de Souza DuranFL, de OliveiraMO, TresES, BruckiSMD, ForlenzaOV, NitriniR, BuchpiguelCA (2020) Brain PET amyloid and neurodegeneration biomarkers in the context of the 2018 NIA-AA research framework: An individual approach exploring clinical-biomarker mismatches and sociodemographic parameters. Eur J Nucl Med Mol Imaging, doi: 10.1007/s00259-020-04714-0.
36.
IvnikRJ, M alecJF, TangalosEG, PetersenRC, KokmenE, KurlandLT (1990) The Auditory-Verbal Learning Test (AVLT): Norms for ages 55 years and older. Psychol Assess2, 304–312.
37.
Malloy-DinizLF, LasmarVA, GazinelliL. S, FuentesD, SalgadoJV (2007) The Rey Auditory-Verbal Learning Test: Applicability for the Brazilian elderly population. Braz J Psychiatry29, 324–329.
38.
LehfeldH, ErzigkeitH (1997) The SKT–a short cognitive performance test for assessing deficits of memory and attention. Int Psychogeriatr9 Suppl 1, 115–121.
39.
FlaksMK, ForlenzaO V, PereiraFS, ViolaLF, YassudaMS (2009) Short cognitive performance test: Diagnostic accuracy and education bias in older Brazilian adults. Arch Clin Neuropsychol24, 301–306.
40.
YamaneT, IshiiK, SakataM, IkariY, NishioT, KatoT, ItoK, SendaM, J-ADNI Study Group (2017) Inter-rater variability of visual interpretation and comparison with quantitative evaluation of. Eur J Nucl Med Mol Imaging44, 850–857.
JackCR, TherneauTM, WeigandSD, WisteHJ, KnopmanDS, VemuriP, LoweVJ, MielkeMM, RobertsRO, MachuldaMM, Graff-RadfordJ, JonesDT, SchwarzCG, GunterJL, SenjemML, RoccaWA, PetersenRC (2019) Prevalence of biologically vs clinically defined alzheimer spectrum entities using the National Institute on Aging-Alzheimer’s Association Research Framework. JAMA Neurol76, 1174–1183.
DukartJ, MuellerK, HorstmannA, VogtB, FrischS, BarthelH, BeckerG, MöllerHE, VillringerA, SabriO, SchroeterML (2010) Differential effects of global and cerebellar normalization on detection and differentiation of dementia in FDG-PET studies. Neuroimage49, 1490–1495.
SilvermanDH, SmallGW, ChangCY, LuCS, Kung De AburtoMA, ChenW, CzerninJ, RapoportSI, PietriniP, AlexanderGE, SchapiroMB, JagustWJ, HoffmanJM, Welsh-BohmerKA, AlaviA, ClarkCM, SalmonE, de LeonMJ, MielkeR, CummingsJL, KowellAP, GambhirSS, HohCK, PhelpsME (2001) Positron emission tomography in evaluation of dementia: Regional brain metabolism and long-term outcome. JAMA286, 2120–2127.
47.
DrzezgaA, LautenschlagerN, SiebnerH, RiemenschneiderM, WillochF, MinoshimaS, SchwaigerM, KurzA (2003) Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer’s disease: A PET follow-up study. Eur J Nucl Med Mol Imaging30, 1104–1113.
48.
HarrisPA, TaylorR, MinorBL, ElliottV, FernandezM, O’NealL, McLeodL, DelacquaG, DelacquaF, KirbyJ, DudaSN, REDCap Consortium (2019) The REDCap consortium: Building an international community of software platform partners. J Biomed Inf95, 103208.
49.
HarrisPA, TaylorR, ThielkeR, PayneJ, GonzalezN, CondeJG (2009) Research electronic data capture (REDCap)–a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inf42, 377–381.
50.
JackCR, WisteHJ, WeigandSD, TherneauTM, KnopmanDS, LoweV, VemuriP, MielkeMM, RobertsRO, MachuldaMM, SenjemML, GunterJL, RoccaWA, PetersenRC (2017) Age-specific and sex-specific prevalence of cerebral β-amyloidosis, tauopathy, and neurodegeneration in cognitively unimpaired individuals aged 50-95 years: A cross-sectional study. Lancet Neurol16, 435–444.
51.
JackCR, WisteHJ, TherneauTM, WeigandSD, KnopmanDS, MielkeMM, LoweVJ, VemuriP, MachuldaMM, SchwarzCG, GunterJL, SenjemML, Graff-RadfordJ, JonesDT, RobertsRO, RoccaWA, PetersenRC (2019) Associations of amyloid, tau, and neurodegeneration biomarker profiles with rates of memory decline among individuals without dementia. JAMA321, 2316–2325.
52.
BurnhamSC, BourgeatP, DoréV, SavageG, BrownB, LawsS, MaruffP, SalvadoO, AmesD, MartinsRN, MastersCL, RoweCC, VillemagneVL, GroupAR (2016) Clinical and cognitive trajectories in cognitively healthy elderly individuals with suspected non-Alzheimer’s disease pathophysiology (SNAP) or Alzheimer’s disease pathology: A longitudinal study. Lancet Neurol15, 1044–1053.
53.
BilgelM, AnY, HelphreyJ, ElkinsW, GomezG, WongDF, DavatzikosC, FerrucciL, ResnickSM (2018) Effects of amyloid pathology and neurodegeneration on cognitive change in cognitively normal adults. Brain141, 2475–2485.
54.
MorminoEC, BetenskyRA, HeddenT, SchultzAP, AmariglioRE, RentzDM, JohnsonKA, SperlingRA (2014) Synergistic effect of β-amyloid and neurodegeneration on cognitive decline in clinically normal individuals. JAMA Neurol71, 1379–1385.
55.
SoldanA, PettigrewC, FaganAM, SchindlerSE, MoghekarA, FowlerC, LiQX, CollinsSJ, CarlssonC, AsthanaS, MastersCL, JohnsonS, MorrisJC, AlbertM, GrossAL (2019) ATN profiles among cognitively normal individuals and longitudinal cognitive outcomes. Neurology92, e1567–e1579.
56.
BurnhamSC, ColomaPM, LiQX, CollinsS, SavageG, LawsS, DoeckeJ, MaruffP, MartinsRN, AmesD, RoweCC, MastersCL, VillemagneVL (2019) Application of the NIA-AA Research Framework: Towards a biological definition of Alzheimer’s disease using cerebrospinal fluid biomarkers in the AIBL study. J Prev Alzheimers Dis6, 248–255.
57.
LandauSM, HarveyD, MadisonCM, KoeppeRA, ReimanEM, FosterNL, WeinerMW, JagustWJ, InitiativeADN (2011) Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI. Neurobiol Aging32, 1207–1218.
58.
WirthM, VilleneuveS, HaaseCM, MadisonCM, OhH, LandauSM, RabinoviciGD, JagustWJ (2013) Associations between Alzheimer disease biomarkers, neurodegeneration, and cognition in cognitively normal older people. JAMA Neurol70, 1512–1519.
59.
KasaiM, MeguroK, HashimotoR, IshizakiJ, YamadoriA, MoriE (2006) Non-verbal learning is impaired in very mild Alzheimer’s disease (CDR 0.5): Normative data from the learning version of the Rey-Osterrieth Complex Figure Test. Psychiatry Clin Neurosci60, 139–146.
60.
KesselsRP, RijkenS, Joosten-Weyn BanninghLW, Van Schuylenborgh-VAN EsN, Olde RikkertMG (2010) Categorical spatial memory in patients with mild cognitive impairment and Alzheimer dementia: Positional versus object-location recall. J Int Neuropsychol Soc16, 200–204.
61.
KawasCH, CorradaMM, BrookmeyerR, MorrisonA, ResnickSM, ZondermanAB, ArenbergD (2003) Visual memory predicts Alzheimer’s disease more than a decade before diagnosis. Neurology60, 1089–1093.
62.
SnitzBE, WeissfeldLA, LopezOL, KullerLH, SaxtonJ, SinghabahuDM, KlunkWE, MathisCA, PriceJC, IvesDG, CohenAD, McDadeE, DekoskyST (2013) Cognitive trajectories associated with β-amyloid deposition in the oldest-old without dementia. Neurology80, 1378–1384.
63.
OkonkwoOC, OhJM, KoscikR, JonaitisE, ClearyCA, DowlingNM, BendlinBB, LarueA, HermannBP, BarnhartTE, MuraliD, RowleyHA, CarlssonCM, GallagherCL, AsthanaS, SagerMA, ChristianBT, JohnsonSC (2014) Amyloid burden, neuronal function, and cognitive decline in middle-aged adults at risk for Alzheimer’s disease. J Int Neuropsychol Soc20, 422–433.
64.
GroberE, VeroffAE, LiptonRB (2018) Temporal unfolding of declining episodic memory on the Free and Cued Selective Reminding Test in the predementia phase of Alzheimer’s disease: Implications for clinical trials. Alzheimers Dement (Amst)10, 161–171.
65.
SlachevskyA, BarrazaP, HornbergerM, Muñoz-NeiraC, FlanaganE, HenríquezF, BravoE, FaríasM, DelgadoC (2018) Neuroanatomical comparison of the “Word” and “Picture” versions of the Free and Cued Selective Reminding Test in Alzheimer’s disease. J Alzheimers Dis61, 589–600.
66.
BruckiSM, NitriniR, CaramelliP, BertolucciPH, OkamotoIH (2003) [Suggestions for utilization of the mini-mental state examination in Brazil]. Arq Neuropsiquiatr61, 777–781.
